Early detection opportunity Position LuCED as a non-invasive, sputum-based early lung cancer detection tool for at-risk populations (smokers and former smokers) to drive collaborations with hospitals, clinics, and payer programs seeking improved early-detection outcomes.

Clinical collaboration Leverage partnerships with cancer centers and research institutes (e.g., Seattle Cancer Care Alliance collaborations) to co-develop and validate Cell-CT driven dashboards and IPN assessment capabilities, expanding to bronchial dysplasia and IPN evaluation services.

3D imaging edge Highlight the Cell-CT 3D imaging platform as a differentiator capable of morphologically recognizing hundreds of biomarkers, targeting pharmaceutical companies developing targeted therapies and companion diagnostics to pair with detected biosignatures.

Funding credibility Utilize NIH BRDG-SPAN grant history and recent board appointments to bolster credibility in discussions with potential investors, grant-funded research partners, and large healthcare entities evaluating innovative diagnostic technologies.

Strategic upsell Explore cross-sell of CellGazer imaging software and broad liquid-biopsy capabilities to labs and CROs seeking scalable, non-invasive diagnostic workflows, with a focus on expanding from lung cancer detection to other cancer biosignatures.